share_log

Tharimmune | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

SEC announcement ·  Jun 13 04:20
Summary by Futu AI
On June 12, 2024, Tharimmune, Inc., a biopharmaceutical company, filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission (SEC). This filing is to register an additional 159,733 shares of common stock under the company's Amended and Restated 2023 Omnibus Equity Incentive Plan. The plan, which was amended to include an 'evergreen' provision, will automatically increase the number of shares available each year starting January 1, 2025, until January 1, 2033. The increase will be the lesser of 5% of the outstanding common stock or a number determined by the Board. The registration statement incorporates by reference the company's previous filings, including its Annual Report on Form 10-K for the year ended December 31, 2023, and Quarterly Reports on Form 10-Q for the quarter ended March 31, 2024. Tharimmune's CEO, Randy Milby, and other executives have signed the filing, which also includes the company's indemnification provisions for directors and officers, as permitted by Delaware law.
On June 12, 2024, Tharimmune, Inc., a biopharmaceutical company, filed a Form S-8 registration statement with the U.S. Securities and Exchange Commission (SEC). This filing is to register an additional 159,733 shares of common stock under the company's Amended and Restated 2023 Omnibus Equity Incentive Plan. The plan, which was amended to include an 'evergreen' provision, will automatically increase the number of shares available each year starting January 1, 2025, until January 1, 2033. The increase will be the lesser of 5% of the outstanding common stock or a number determined by the Board. The registration statement incorporates by reference the company's previous filings, including its Annual Report on Form 10-K for the year ended December 31, 2023, and Quarterly Reports on Form 10-Q for the quarter ended March 31, 2024. Tharimmune's CEO, Randy Milby, and other executives have signed the filing, which also includes the company's indemnification provisions for directors and officers, as permitted by Delaware law.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Doc 5

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.